Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.
StockStory.org on MSN
Unpacking Q3 earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) in the context of other therapeutics stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several ...
Biogen Inc. stock reached a 52-week high of 185.59 USD, marking a significant milestone for the biotechnology company. According to InvestingPro data, the stock is trading at 184.58 USD, just 0.99% ...
Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...
If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the ...
On Wednesday, Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales of $2.46 billion, up 2% year over year on ...
Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are covering the firm, MarketBeat.com reports. Eighteen analysts have rated ...
UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback